The human immunodeficiency virus (HIV) evades the body’s immune defenses through multiple mutations, and antibodies produced by the host immune system against HIV follow complex and untraceable evolutionary pathways. This complexity makesRead More…
Immuno-Oncology Therapy (I-O) refers to a therapy that kills tumor cells by activating the body’s immune system. According to their different mechanisms of action, immunotherapeutic drugs can be divided into six categories.Read More…
In a recent study published in an international magazine of Immunity, scientists at the University of Southampton have developed a new antibody that could hold the key to unlocking cancers’ defense againstRead More…
The International Union Against Cancer believes that one-third of cancers are preventable, one-third can be cured if diagnosed early, and one-third can be alleviated to help prolong patients’ life. Cancer control isRead More…
Immunotherapy with checkpoint inhibitors is more effective in cancer patients who have elevated numbers of specific types of immune cells inside their tumors, a study suggests. Patients with a favorable combination of immuneRead More…
The receptors, found in so-called elite controllers who don’t need medications to keep the virus in check, suggest a new path toward immunotherapy. Researchers trying to develop new treatments, or even aRead More…
Unlike the mechanism of action of traditional treatments, immunotherapy is uniquely characterized by its long-term response and survival in efficacy, unconventional delayed response and pseudo-progression in response mode, a new assessment endpointRead More…
“Two new studies use new models to identify genetic targets and test promising treatments for adrenal cancer. One patient was treated with the immunotherapy pembrolizumab and now more than a year afterRead More…
There is no doubt that this year marks the beginning of CAR-T therapy owing to the advent of two CAR-T therapies and the changes that these therapies have brought to the lives ofRead More…
Actemra/RoActemra® is the first FDA approved drug for treatment of serious or fatal cytokine release syndrome (CRS) caused by CAR-T therapy; CAR-T cell therapy is an immunotherapy used to treat certain typesRead More…